Cargando…

CXCL5: A coachman to drive cancer progression

Chemokines are a class of pro-inflammatory cytokines that can recruit and activate chemotactic cells. C‐X‐C motif chemokine ligand 5 (CXCL5) is a member of the chemokine family binding CXCR2 (C-X-C Motif Chemokine Receptor 2), a G-protein coupled receptor. Accumulated evidence has shown that dysregu...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Jie, Jiang, Rongqi, Meng, Enqing, Wu, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376318/
https://www.ncbi.nlm.nih.gov/pubmed/35978824
http://dx.doi.org/10.3389/fonc.2022.944494
_version_ 1784768140983402496
author Deng, Jie
Jiang, Rongqi
Meng, Enqing
Wu, Hao
author_facet Deng, Jie
Jiang, Rongqi
Meng, Enqing
Wu, Hao
author_sort Deng, Jie
collection PubMed
description Chemokines are a class of pro-inflammatory cytokines that can recruit and activate chemotactic cells. C‐X‐C motif chemokine ligand 5 (CXCL5) is a member of the chemokine family binding CXCR2 (C-X-C Motif Chemokine Receptor 2), a G-protein coupled receptor. Accumulated evidence has shown that dysregulated CXCL5 participates in tumor metastasis and angiogenesis in human malignant tumors. In this review, we summarized the advances in research on CXCL5, including its dysregulation in different tumors and the mechanism associated with tumor behavior (formation of the immunosuppressive microenvironment, promotion of tumor angiogenesis, and metastasis). We also summarized and discussed the perspective about the potential application of CXCL5 in tumor therapy targeting the tumor inflammatory microenvironment.
format Online
Article
Text
id pubmed-9376318
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93763182022-08-16 CXCL5: A coachman to drive cancer progression Deng, Jie Jiang, Rongqi Meng, Enqing Wu, Hao Front Oncol Oncology Chemokines are a class of pro-inflammatory cytokines that can recruit and activate chemotactic cells. C‐X‐C motif chemokine ligand 5 (CXCL5) is a member of the chemokine family binding CXCR2 (C-X-C Motif Chemokine Receptor 2), a G-protein coupled receptor. Accumulated evidence has shown that dysregulated CXCL5 participates in tumor metastasis and angiogenesis in human malignant tumors. In this review, we summarized the advances in research on CXCL5, including its dysregulation in different tumors and the mechanism associated with tumor behavior (formation of the immunosuppressive microenvironment, promotion of tumor angiogenesis, and metastasis). We also summarized and discussed the perspective about the potential application of CXCL5 in tumor therapy targeting the tumor inflammatory microenvironment. Frontiers Media S.A. 2022-08-01 /pmc/articles/PMC9376318/ /pubmed/35978824 http://dx.doi.org/10.3389/fonc.2022.944494 Text en Copyright © 2022 Deng, Jiang, Meng and Wu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Deng, Jie
Jiang, Rongqi
Meng, Enqing
Wu, Hao
CXCL5: A coachman to drive cancer progression
title CXCL5: A coachman to drive cancer progression
title_full CXCL5: A coachman to drive cancer progression
title_fullStr CXCL5: A coachman to drive cancer progression
title_full_unstemmed CXCL5: A coachman to drive cancer progression
title_short CXCL5: A coachman to drive cancer progression
title_sort cxcl5: a coachman to drive cancer progression
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376318/
https://www.ncbi.nlm.nih.gov/pubmed/35978824
http://dx.doi.org/10.3389/fonc.2022.944494
work_keys_str_mv AT dengjie cxcl5acoachmantodrivecancerprogression
AT jiangrongqi cxcl5acoachmantodrivecancerprogression
AT mengenqing cxcl5acoachmantodrivecancerprogression
AT wuhao cxcl5acoachmantodrivecancerprogression